Clinical Trial

A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

Name: A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung — clinical trial record (NCT07561645)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ALPINE 2

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.

Trial Details

NCT Number	NCT07561645
Lead Sponsor	Technische Universität Dresden
Conditions	Large Cell Neuroendocrine Carcinoma of the Lung
Enrollment	75 participants
Start Date	2026-07
Primary Completion	2032-04 (estimated)
Study Completion	2032-04 (estimated)
Updated on ClinicalTrials.gov	2026-05-01